Suchergebnisse - "WOH1JD9AR8"

PubPharm (1.392)

81

Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice

enthalten in: Environmental toxicology and pharmacology | 2023

von Elkatary, R. | El Beltagy, H. | Abdo, V. | +3

82

Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer

enthalten in: The Lancet. Oncology | 2023

von Martini, A. | Fallara, G. | Ploussard, G. | +1

CommentOn: Lancet Oncol. 2023 Oct;24(10):1094-1108. - PMID 37714168

83

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel) : final prespecified overall survival results of a randomised, double-blind, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Saad, F. | Clarke, N. | Oya, M. | +16

CommentIn: Lancet Oncol. 2023 Oct;24(10):1056-1057. - PMID 37797626

84

Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer

enthalten in: Journal of cancer research and clinical oncology | 2023

von Yue, W. | Yupeng, G. | Jun, C. | +1

85

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation : a case report

enthalten in: Journal of medical case reports | 2023

von Del Giglio, A. | da Costa Aguiar Alves, B. | Murad, A. | +1

86

Physiologically-based pharmacokinetic modeling for optimal dosage prediction of olaparib when co-administered with CYP3A4 modulators and in patients with hepatic/renal impairment

enthalten in: Scientific reports | 2023

von Gao, D. | Wang, G. | Wu, H. | +1

87

Exceptional Response to Olaparib : A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 Mutations

enthalten in: JCO precision oncology | 2023

von Haggstrom, L. | Tucker, K. | Williams, R. | +4

88

Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Lheureux, S. | Prokopec, S. | Oldfield, L. | +19

89

Development and Comparative Evaluation of Two Different Label-Free and Sensitive Fluorescence Platforms for Analysis of Olaparib : A Recently FDA-Approved Drug for the Treatment of Ovarian and Breast Cancer

enthalten in: Molecules (Basel, Switzerland) | 2023

von Darwish, I. | Khalil, N.

90

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer : the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

enthalten in: Nature communications | 2023

von Kim, Y. | Park, B. | Kim, J. | +8